Search

Author/Creator Frias, Juan P

1. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Issue 11 (November 2019)

Authors:
Lingvay, Ildiko; Catarig, Andrei-Mircea; Frias, Juan P; Kumar, Harish; Lausvig, Nanna L; le Roux, Carel W; Thielke, Desirée; Viljoen, Adie; McCrimmon, Rory J
Journal:
Lancet
Issue:
Volume 7:Issue 11(2019)
Page Start:
834
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Issue 10300 (14th August 2021)

Authors:
Ludvik, Bernhard; Giorgino, Francesco; Jódar, Esteban; Frias, Juan P; Fernández Landó, Laura; Brown, Katelyn; Bray, Ross; Rodríguez, Ángel
Journal:
Lancet
Issue:
Volume 398:Issue 10300(2021)
Page Start:
583
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Issue 10313 (13th November 2021)

Authors:
Del Prato, Stefano; Kahn, Steven E; Pavo, Imre; Weerakkody, Govinda J; Yang, Zhengyu; Doupis, John; Aizenberg, Diego; Wynne, Alan G; Riesmeyer, Jeffrey S; Heine, Robert J; Wiese, Russell J; Ahmann, Andrew J; Arora, Samir; Ball, Eric M; Calderon, Rafael B; Butuk, David J; Chaychi, Leila; Chen, Mic...
Journal:
Lancet
Issue:
Volume 398:Issue 10313(2021)
Page Start:
1811
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search